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Abstract: Aging is associated with a vasoconstrictive, pro-coagulant, and pro-inflammatory profile of
arteries and a decline in the bioavailability of the endothelium-derived molecule nitric oxide. Dietary
nitrate elicits vasodilatory, anti-coagulant and anti-inflammatory effects in younger individuals,
but little is known about whether these benefits are evident in older adults. We investigated
the effects of 140 mL of nitrate-rich (HI-NI; containing 12.9 mmol nitrate) versus nitrate-depleted
beetroot juice (LO-NI; containing ≤0.04 mmol nitrate) on blood pressure, blood coagulation, vascular
inflammation markers, plasma nitrate and nitrite before, and 3 h and 6 h after ingestion in healthy
older adults (five males, seven females, mean age: 64 years, age range: 57–71 years) in a randomized,
placebo-controlled, crossover study. Plasma nitrate and nitrite increased 3 and 6 h after HI-NI
ingestion (p < 0.05). Systolic, diastolic and mean arterial blood pressure decreased 3 h relative to
baseline after HI-NI ingestion only (p < 0.05). The number of blood monocyte-platelet aggregates
decreased 3 h after HI-NI intake (p < 0.05), indicating reduced platelet activation. The number of
blood CD11b-expressing granulocytes decreased 3 h following HI-NI beetroot juice intake (p < 0.05),
suggesting a shift toward an anti-adhesive granulocyte phenotype. Numbers of blood CD14++CD16+
intermediate monocyte subtypes slightly increased 6 h after HI-NI beetroot juice ingestion (p < 0.05),
but the clinical implications of this response are currently unclear. These findings provide new
evidence for the acute effects of nitrate-rich beetroot juice on circulating immune cells and platelets.
Further long-term research is warranted to determine if these effects reduce the risk of developing
hypertension and vascular inflammation with aging.
Keywords: beetroot juice; dietary nitrate; anti-thrombotic effects; anti-adhesive effects; low-grade
inflammation; thrombosis; blood pressure; aging; preserving vascular health
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1. Introduction
Advancing age is a major risk factor for cardiovascular disease (CVD) [1]. Developing lifestyle-based
strategies to prevent adverse changes in arteries with aging has therefore become increasingly important
for physiological and biomedical research [1]. Vascular endothelial dysfunction is recognized as
a key mechanism underlying cardiovascular pathologies including hypertension; atherosclerosis
and thrombosis [1,2]. It develops with aging, and is characterized by several phenotypic changes
including alterations toward a vasoconstrictive; pro-inflammatory and pro-coagulant profile [1,3].
The endothelium-derived molecule nitric oxide (NO) has a protective influence on all of these processes.
Therefore, the age-associated decline in the production and/or bioavailability of NO plays a central role
in the impairment of vascular function [1,2]. Endogenously produced by NO synthases (NOS) including
endothelial NOS, NO is an important signaling molecule with various physiological functions in the
human body [2,4]. NO relaxes vascular smooth muscle cells; contributes to endothelium-dependent
vasodilation; and inhibits platelet aggregation and leukocyte adhesion through the cyclic guanosine
monophosphate pathway [4].
There has been an increasing interest in the preventative and therapeutic potential of the
nitrate-nitrite-NO pathway as an alternative mechanism of NO production [2,5–7]. In this pathway,
dietary nitrate is absorbed into the circulation, taken up by the salivary glands, and reduced to
nitrite by oral commensal bacteria [5–7]. Nitrite in swallowed saliva is then absorbed, and, upon
entry into the systemic circulation, further reduced to NO by metalloproteins (e.g., hemoglobin
and deoxyhemoglobin), enzymes (e.g., xanthine oxidoreductase) and other compounds with redox
potential (e.g., polyphenols) [5–7]. Nitrite reduction to NO is accelerated in low oxygen or acidic
conditions [5–7]. Recent research has suggested that the beneficial cardiovascular health properties
of a diet rich in plant foods may be particularly related to the high inorganic nitrate content of
vegetables such as green leafy or root vegetables [2,5,8]. A number of studies have shown benefits
of dietary nitrate in physiological and clinical settings [9,10]. A meta-analysis by Siervo et al. [8]
indicated that inorganic nitrate and beetroot juice supplementation was associated with a significant
reduction of blood pressure in adults. Recent studies have also reported beneficial effects of dietary
nitrate on the inflammatory and thrombotic profile in young healthy individuals [11], and middle-aged,
hypercholesterolemic patients [12]. By contrast, there is only little information available on the potential
beneficial health effects of dietary nitrate, and particularly, nitrate-rich foods in older individuals.
Dietary supplementation of inorganic nitrate with either beetroot juice [9,13] or sodium nitrate reduced
resting blood pressure in healthy older adults [13], lowered daily systolic blood pressure in overweight
older individuals [9], and improved several markers of endothelial function in older adults with
moderately increased risk for CVD [10].
On the contrary, a two-week supplementation period with nitrate-rich beetroot juice had no
effect on 24-h ambulatory blood pressure in obese older individuals with type 2 diabetes [14]. Data
on whether the effects of dietary nitrate on thrombo-inflammatory biomarkers reported previously
in younger adults are also evident in older adults are scarce and insufficient. Counteracting the
development of chronic low-grade inflammation and adverse hemostatic changes is considered
a central strategy to preserve vascular health with advancing aging [1,3,15]. Hence, there is a clear
rationale to examine the potential of dietary nitrate in older adults in this context.
The aim of this study was therefore to investigate the acute effects of a single dose of nitrate-rich
versus nitrate-depleted beetroot juice on blood pressure, biomarkers of vascular inflammation and
hemostasis in older adults in the hours after juice consumption. We hypothesized that dietary inorganic
nitrate ingestion would reduce blood pressure, and elicit beneficial effects on markers of leukocyte and
platelet activation, and hemostasis in healthy older adults.
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2. Materials and Methods
2.1. Study Participants
Seventeen older adults were recruited for this study through advertisements in local newspapers
from the general population of greater Brisbane, Queensland, Australia, and through e-mail
communication from Queensland University of Technology staff members. All participants provided
written, informed consent before their inclusion in the study. Prior to the enrolment into the study, all
participants were assessed by a medical physician and classified as clinically healthy. This medical
entrance examination included a standard medical history questionnaire, resting electrocardiography,
height, weight, body mass index (BMI) and blood pressure measurements. The participants also
completed a physical activity questionnaire. Exclusion criteria were as follows: BMI (in kg/m2) <18 or
>35, any evidence of acute or chronic disease such as severe cardiovascular disease, pulmonary, neural
or musculoskeletal disease, osteoporotic fractures and diabetes, acute or chronic pain or disability,
smoking, and the use of anti-coagulation, non-steroidal anti-inflammatory, or statin-related drugs.
Based on these exclusion criteria, one participant was excluded from the study. Four other participants
were unavailable to attend their scheduled trial days and took no further part in the study. The data
from another participant were excluded from the data analysis due to difficulty with the blood
collections. In total, 12 of the original 17 volunteers completed both study visits. Of these twelve
participants (five males and seven females; mean age: 64 years, age range: 57–71 years), one was taking
low-dose medication for hypertension (angiotensin converting enzyme inhibitor), one was taking
a xanthine oxidase inhibitor, and another one reported using a proton pump inhibitor and a selective
serotonin and norepinephrine reuptake inhibitor. The participants’ characteristics are summarized in
Table 1. Approval for all experimental procedures was obtained from the University Human Research
Ethics Committee at Queensland University of Technology (approval number 1500000881).
Table 1. Characteristics of the study participants.
Anthropometric Characterististics and Medications Baseline Values
Age (Years; Indicated as Mean Age and Range) 64 (57–71)
Sex (male:female) 5:7
Body mass index (BMI) (kg/m2) 25.7 ± 4.2
Baseline systolic blood pressure (mmHg) 133.0 ± 16.6
Baseline diastolic blood pressure (mmHg) 88.6 ± 8.8
Waist circumference (cm) 96.0 ± 12.2
Medications (n) 4
ACE inhibitors 1
PPI 1
SSNRI 1
XOI 1
Values are presented as mean ± standard deviation (SD). Abbreviations: ACE, angiotensin converting enzyme;
PPI, proton pump inhibitor; SSNRI, selective serotonin and norepinephrine reuptake inhibitor; XOI, xanthine
oxidase inhibitor.
2.2. Study Design
The study involved a randomized, double-blind, placebo-controlled, balanced crossover design
with a washout period of at least two weeks. After enrollment into the study, the participants were
allocated to an intervention plan by block random assignment based on computer-generated random
numbers. The interventions consisted of the ingestion of a single dose of either 140 mL of nitrate-rich
beetroot juice (HI-NI) or 140 mL of nitrate-depleted beetroot juice as the placebo control (LO-NI).
All products were obtained from the same supplier (Beet It, James White Drinks, Ipswich, UK).
The nitrate-depleted beetroot juice was generated using a standard ion exchange resin, as described
previously [13]. The 140 mL of HI-NI beetroot juice contained 12.9 mmol nitrate (NO3−), whereas
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the 140 mL of LO-NI beetroot juice contained between 0.01 mmol and 0.04 mmol nitrate, according
to the manufacturer batch analysis. The two juices were indistinguishable by taste, color, smell and
packaging. The investigators involved in the data acquisition and analysis were blind to the trial
allocation until the study had been completed and all analyses were performed.
The participants were provided with a list of high-nitrate foods and instructed to avoid foods on
this list for 48 h preceding each of the two trial days. They recorded their food intake for 48 h before
the first trial day, firstly to check that they adhered to the dietary protocol, and secondly to replicate
this food consumption in the 48 h preceding the second trial day. The participants were also required
to refrain from caffeine and alcohol consumption. They were also required to abstain from antibacterial
mouthwash and chewing gum in the 24 h preceding each trial, because these might have influences
the oral microbiome and nitrate metabolism [6,16]. In the 24 h preceding and throughout the trial
period on each trial day, the participants were instructed to avoid any strenuous exercise.
The participants were required to attend our laboratories at the Institute of Health and Biomedical
Innovation, Queensland University of Technology, at Kelvin Crove campus, Brisbane on three
occasions. These included the medical entrance examination and the two trial days. On the trial
days, all participants arrived at the laboratory in the morning, between 7:00 a.m. and 8:30 a.m.,
in a rested state, following an overnight fast. Upon arrival at the laboratory, participants were provided
with a triaxial-accelerometry-based activity monitor (GENEactiv, Activinsights Ltd., Cambridgeshire,
UK) to verify that they maintained low physical levels during the entire trial period. At this time,
resting blood pressure was also measured, and a venous blood sample was collected for assessment of
a baseline for all measures (PRE). Participants then consumed either HI-NI or LO-NI beetroot juice,
as reported above, in addition to a standardized, low nitrate breakfast (Table 2). Resting blood pressure
measurements and blood sample collections were then again performed 3 h and 6 h post-ingestion.
After the 3 h blood pressure measurement and blood sample collection, the participants were provided
another standardized low-nitrate meal.
Table 2. Energy and macronutrient content of standardized low-nitrate meals provided to participants.
Breakfast
Food Brand Amount Energy (kJ) Fat (g) Carbo-Hydrates (g) Protein (g)
High-fiber low-sugar cereal biscuit Weet-bix, Sanitarium 4 biscuits 983 0.9 44.2 8.2
Milk † Devondale 200 mL 538 6.8 10.2 6.6
Apple Juice Just Juice 200 mL 374 <1 21 <1
Total 1895 7.7 75.4 14.8
Snack
Food Brand Amount Energy (kJ) Fat (g) Carbo-Hydrates (g) Protein (g)
Oat Slice
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Breakfast
Food Brand Amount Energy (kJ) Fat (g) Carbo-hydrates (g) Protein (g)
High-fiber low-sugar cereal biscuit Weet-bix, Sanitarium 4 biscuits 983 0.9 44.2 8.2 
Milk † Devondale 200 mL 538 6.8 10.2 6.6 
Apple Juice Just Juice 200 mL 374 <1 21 <1 
Total 1895 7.7 75.4 14.8 
Snack
Food Brand Amount Energy (kJ) Fat (g) Carbo-hydrates (g) Protein (g)
Oat Slice ʎ Uncle Toby’s 1 bar 600 6.1 19.1 2.1 
Apple * Gala 1 whole fruit 441 0 22.9 0.6 
Total 1041 6.1 42 2.7 
* Macronutrient data sourced from calorieking.com.au. † Option as provided for one vegan 
participant: 200 mL of soy milk (energy = 662 kJ; fat = 9.4 g; carbohydrates = 6 g; protein = 6.2 g).  
ʎ Option as provided for one vegan participant: 30 grams of mixed nuts (energy = 765 kJ; fat = 17.5 g; 
carbohydrates = 2.4 g; protein = 5.0 g). All nutritional values sourced from packaging, unless 
otherwise stated. Breakfasts were provided immediately following beetroot juice ingestion. Snacks 
were provided immediately after 3 h assessments.  
2.3. Blood Pressure Measurements and Power Density Spectral Analysis 
Blood pressure measurements were performed in seated position, in a quiet, light controlled 
room with an ambient temperature of between 19–21 °C. Blood pressure was measured by light 
photoplethysmography (Finapres Medical Systems, Ohmeda, Madison, WI, USA). To record 
systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP), a 
photoplethysmographic cuff was placed on the left middle finger. This procedure permitted 
Uncle Toby’s 1 bar 600 6.1 19.1 2.1
Apple * Gala 1 wholefruit 441 0 22.9 0.6
Total 1041 6.1 42 2.7
* Macronutrient data sourced from calorieking.com.au. † Option as provided for one vegan participant: 200 mL
of soy milk (energy = 662 kJ; fat = 9.4 g; carbohydrates = 6 g; protein = 6.2 g).
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as provided for one
vegan participant: 30 grams of mixed nuts (energy = 765 kJ; fat = 17.5 g; carbohydrates = 2.4 g; protein = 5.0 g).
All nutritional values sourced from packaging, unless otherwise stated. Breakfasts were provided immediately
following beetroot juice ingestio . Snacks we provided immediately after 3 h a sessments.
2.3. Blood Pressure Measurements and Power Density Spectral Analysis
Blood pressure measurements were performed in seated position, in a quiet, light controlled
room with an ambient temperature of between 19–21 ◦C. Blood pressure was measured by
light photoplethysmography (Finapres Medical Systems, Ohmeda, Madison, WI, USA). To record
systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP),
a photoplethysmographic cuff was placed on the left middle finger. This procedure permitted
non-invasive, beat-by-beat blood pressure recordings. Participants were asked to remain in a seated
position for a minimum 10 min to stabilize blood pressure. During this time, the finger cuff was fitted
and an automatic calibration function was used for a minimum of 3 min prior to ensure accurate blood
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pressure readings. This calibration function was deactivated during the recording period to prevent
signal distortion. Blood pressure signals were recorded at 1 kHz for 12 min at each time point through
an analogue-to-digital converter (Powerlab 16/30 model, ADInstruments, Colorado Springs, CO, USA)
using commercially available software (LabChart version 7.3.7, ADInstruments, Sydney, Australia).
Data were exported from LabChart at 1 Hz. Blood pressure variability arising from neurohumoral
regulation mechanisms was assessed by power spectral density (PSD) analysis [17]. Time-based data
for SBP were transformed into the frequency domain using the fast Fourier transformation [18]. Total
power for the first 512 s of each experimental time point was calculated and expressed as mmHg2.
The very low frequency (VLF) domain between 0.02 Hz and 0.07 Hz is associated with a myogenic
response of the vasculature. The low frequency (LF) domain between 0.07 Hz and 0.15 Hz is linked to
the myogenic and sympathetic nervous system response. The high frequency (HF) domain between
0.15 Hz and 0.4 Hz is associated with respiration rate and, possibly, endothelial-derived NO [17].
For BP, HR, and PSD analysis, all data were subjected to artifact extraction and filtering following
export. For artifact extraction, the mean and standard deviation (SD) were calculated for each
individual measurement. Values greater than 2SD on either side of the mean were excluded [19].
Extracted values were replaced through cubic spline interpolation.
2.4. Blood Sample Collections
At each sampling time-point, approximately 27 mL of blood was collected through a 21-gauge
butterfly needle inserted into an antecubital vein. Blood was collected into vacutainers (BD Biosciences,
San Jose, CA, USA), containing either 3.2% buffered sodium citrate (for whole blood hemostasis and
flow cytometry analyses), ethylenediamine tetraacetic acid (EDTA; for plasma nitrate analysis), and
lithium-heparin (for plasma nitrite analysis). For plasma analyses, blood samples were centrifuged at
1500× g for 10 min at 22 ◦C, within 3 min of collection. Plasma was aliquoted, frozen in liquid nitrogen,
and stored at minus 80 ◦C until analysis.
2.5. Plasma Nitrite and Nitrate
Plasma nitrate concentrations were quantified using a kit and calibrators from Cayman chemical
(Ann Arbor, MI, USA). All samples were defrosted and subjected to ultrafiltration using a 10–kDa
filter from Merk Millipore Ltd. (Tullagreen, Ireland). Of the resulting solution, 40 µL was used for the
analysis. Standards were prepared as per the manufacturer instructions.
Plasma nitrite concentrations were measured (within 30 min of defrosting) by chemiluminescence
using Ionics/Sievers nitric oxide analyzer (NOA 280i), as per manufacturer’s instructions
(Sievers Instruments, Boulder, CO, USA). Potassium iodide in acetic acid was used as the reductant,
which has the potential to convert nitrite to NO but is insufficient to reduce any higher oxides of
nitrogen such as nitrate and thus is relatively specific for nitrite.
2.6. Rotational Thrombelastometry
ROTEM (Tem International, Munich, Germany) analysis uses a viscoelastometric method
(thrombelastometry) to test hemostasis status in whole blood [20]. Within 4 h of blood sampling,
four assays were performed: (1) EXTEM (extrinsically-activated test using tissue factor; assesses the
extrinsic coagulation pathway); (2) INTEM (intrinsically-activated test using ellagic acid; assesses
the intrinsic coagulation pathway); (3) FIBTEM (extrinsically-activated test using tissue factor and
the platelet inhibitor cytochalasin D; assesses fibrin contribution to clot strength); and (4) APTEM
(extrinsically-activated test using the fibrinolysis inhibitor aprotinin; assesses hyperfibrinolysis).
All assays were performed according to instrument instructions and were performed for a minimum
of 30 min at 37 ◦C. ROTEM variables that were measured included: clotting time (CT, seconds),
clot formation time (CFT, seconds), alpha angle (α, degrees), maximum clot firmness (MCF, mm),
lysis index at 30 min (LI30), and maximum clot elasticity (MCE). Clotting time provides information
concerning the first signs of clot detection and describes how rapidly fibrin formation occurs, and are
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routinely used in clinical settings to examine coagulation profiles. Clot formation time is the time from
clotting time until a fixed level of firmness is reached, and describes the rate of initial clot formation
that is mediated by fibrin, activated factor XIII, and thrombin-activated platelets. The α angle is
used to determine speed of clot formation. Maximum clot firmness is the maximum clot amplitude
achieved prior to fibrinolysis. Lysis index at 30 min is the clot firmness at 30 min after clotting time, and
indicates the rate at which fibrinolysis occurred. Maximum clot elasticity is derived from maximum
clot firmness (MCF) and indicates the platelet contribution of the clot. Maximum clot elasticity (MCE)
was determined by the mathematical formula: MCE = (100 × MCF)/(100 − MCF). To determine how
platelets contributed to the clot elasticity, the following mathematical formula was used: MCEplatelet
= MCEEXTEM − MCEFIBTEM. This method has been shown to specifically measure the contribution
of platelets to the clot firmness [21]. Quality control was performed using quality-controlled plasma
samples with known clotting parameters (ROTROL-N and ROTROL-P) at regular intervals.
2.7. Plasma Hemostasis Analysis
Prothrombin time and activated partial thromboplastin time were measured to provide a clinical
indication of the extrinsic and intrinsic coagulation pathways. Analysis of prothrombin time
and activated partial thromboplastin time was measured using the KC4 Amelung coagulometer
(Trinity Biotech, Bray, Co Wicklow, Ireland). Briefly, prothrombin time was determined by incubating
50 µL of citrated plasma for 3 min before addition of 100 µL of lyophilized thromboplastin and CaCl2
to initiate clotting (Neoplastine CI Plus, Stago, Parsippany, NJ, USA). Activated partial thromboplastin
time was determined by incubating 50 µL of citrated plasma at 37 ◦C for 3 min with 50 µL of activated
partial thromboplastin reagent (TriniCLOT activated partial thromboplastin, Trinity Biotech, Bray,
Co Wicklow, Ireland). Clotting was initiated with 50 µL of 30 mM CaCl2 and clotting time was recorded.
All measurements were performed in triplicate.
2.8. Flow Cytometry
Flow cytometric analysis was conducted to measure blood leukocyte-platelet aggregates, blood
leukocyte and platelet activation, monocyte population subsets, and platelet P-selectin expression.
Monocytes, granulocytes and platelets were immunolabeled in whole blood to prevent artifactual
platelet activation that may occur through the isolation of these cells. All monoclonal antibodies
were obtained from BD Biosciences. Briefly, 50 µL of whole blood were incubated for 20 min at room
temperature with pre-conjugated monoclonal antibodies selective for monocyte-CD14 (Alex fluor 647;
AF647), a granulocyte-CD16 (allophycocyanin-conjugated: APC-H7), platelet-CD42a (fluorescein
isothiocyanate; FITC), Mac-1/αM-CD11b (phycoerythrin; PE), P-selection-CD62P (Brilliant Violet™;
BV421) or isotype matched controls for each fluorochrome (all, BD Biosciences, Eight Mile Plains,
Australia). Samples were then fixed and red cells were lysed via the addition of 500 µL of FACS-Lyse
solution (BD Biosciences, Eight Mile Plains, Australia). Flow cytometry was conducted using
a FACSAria flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) with a minimum of 5000 cells
for each population collected. Analyses were performed using FlowJo software (Treestar, Inc.,
San Carlos, CA, USA). The gating strategy for population isolation and relative expression is illustrated
in Figure 1.
2.9. Leukocyte-Platelet Aggregation and Activation
Granulocytes and monocytes were identified using forward and side scatter characteristics.
Granulocytes and monocytes were confirmed, using histogram analysis to be CD16+ (CD14−) and
CD14+ respectively. The percentage of granulocyte-platelet aggregates (% GPA) and monocyte-platelet
aggregates (% MPA) were determined as the proportion of co-expressing CD16 or CD14 and CD42a
platelet marker for each population. Leukocyte activation was measured by the relative expression of
CD11b Mac-1/αM marker for each population determined by the median fluorescence intensity (MFI).
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Figure 1. Flow cytometry gating strategy. Granulocyte and monocyte populations gated based on
their forward (FSC) vs. side scatter (SSC) properties (A). Granulocyte populations were confirmed to
be CD16+ with granulocyte-platelet aggregates identified by quadrant gating as CD16+ and CD42a+
cells (B) and relative expression of αM integrin expression on granulocytes defined as CD11b+ (blue)
compared to unstained control (red) via histogram (C). Monocyte populations were confirmed to be
CD14+. Monocytes sub-populations are defined by gating of CD14++CD16− (classical), CD14++CD16+
(intermediate) and CD14+CD16+ (non-classical) (D). Monocyte-platelet aggregates were identified by
quadrant gating as CD14+ and CD42a+ cells (E). Relative expression of αM integrin expression on
m nocytes define as CD11b+ (blue) co p red to unstained control (red) via histogram (F). Platelet
p pu ion was identified using histogram analysis of cells CD42a+ (G) wi h P-selectin expression on
platelets determined through CD62P histogram analysis of CD42a+ population (H).
2.10. Monocyte Population Subsets
To identify monocyte population subsets, gated CD14+ monocytes were plotted against CD16.
Monocyte subsets were defined as classical (CD14++CD16−), intermediate (CD14++CD16+) and
non-classical (CD14+CD16+) as per previously defined nomenclature [22].
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2.11. Platelet P-Selectin
Platelet population was identified using a histogram gate to be CD42a+ positive. The relative
expression of P-selectin (CD62P) in CD42a+ platelets was reported as the MFI of CD42a+/CD62P+ cells.
2.12. Statistical Analysis
The sample size was calculated based on previously published data on blood pressure changes
following beetroot juice intake in healthy older adults compared with placebo [13]. For detecting
a difference with a power of 80% at significance level of α = 0.05, and the conservative assumption of
an autocorrelation of 0.9 between repeated measures, a sample size of 13 was required. This figure was
inflated by 20% as the estimated dropout rate, resulting in a final sample size of 17.
GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla, CA, USA) was used for
statistical analysis. Missing data points were imputed using the expectation-maximum method [23].
Data analysis included baseline comparisons using paired t-tests. Two-way repeated measures ANOVA
was used to determine the main effects of time, and interaction effects between time and trial. Significant
effects of trial and time were analyzed using post hoc tests and a Bonferroni correction. Statistical
significance was set at a p value of < 0.05. Data are presented as mean ± standard deviation (SD).
3. Results
3.1. Plasma Nitrate and Nitrite Levels
Baseline plasma concentrations of nitrate and nitrite were not significantly different in both trials.
A time (p < 0.05), and a time × trial interaction (p < 0.05) were observed for both plasma nitrate and
nitrite. Plasma nitrate and nitrite concentration increased at both 3 h and 6 h post-ingestion in the
HI-NI trial (p < 0.05), but not the LO-NI trial (Figure 2A,B).
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(SD), n = 12. **** p < 0.0001, significantly different compared with baseline (PRE). PRE, pre-ingestion
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3.2. Systolic, Diastolic and Mean Arterial Blood Pressure, and Power Spectral Density of Systolic
Blood Pressure
Baseline levels of SBP, DBP, MAP, and heart rate were not different between trials (Figure 3A–C).
A significant effect of time was observed in SBP, DBP and MAP (p < 0.05). Post hoc analysis revealed
significantly lower values at 3 h post-ingestion as compared to baseline for SBP, DBP, and MAP in the
HI-NI trial, but not the LO-NI trial (Figure 3A–C). The mean changes and 95% confidential intervals
(CI; reported in brackets) for SBP, DBP, and MAP 3 h after ingestion of the HI-NI beetroot juice were
−7.9 mmHg (−1.1 to −14.7 mmHg), −5.7 mmHg (−0.6 to −10.8 mmHg), and −6.4 mmHg (−1.2 to
−11.6 mmHg), respectively. In the HI-NI trial, SBP, DBP and MAP had returned to baseline levels at
6 h post-ingestion. A significant increase in SBP between baseline and 6 h post-ingestion was found
in the LO-NI trial only. A trend towards a significant effect of time × trial interaction was evident in
SBP (p = 0.054; Figure 3A). A trend towards time × trial interaction effects was evident in the VLF
bandwidth (p = 0.06), with an increase in total power for the VLF band observed at 3 h post-ingestion
in the HI-NI trial only (Table 3).
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Figure 3. Systolic blood pressure (SBP) (A); diastolic blood pr ssure (DBP) (B); and mean arterial
pressure (MAP) (C) following nitrate-rich (HI-NI) versus nitrate-depleted (LO-NI) beetroot juice
ingestions. Data obtained from 12 participants and expressed as mean ± standard deviation (SD).
* p < 0.05; significantly different changes compared with baseline (PRE): 3 h POST, 3 h post-ingestion;
6 h POST, 6 h post-ingestion.
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3.3. Granulocyte-Platelet and Monocyte-Platelet Aggregation
There was no significant difference in GPA (Figure 4A). Whereas no interaction effect was observed
between the trials, an overall effect of time on MPA levels in whole blood was observed following both
the LO-NI and the HI-NI trial (p < 0.01) (Figure 4C). Furthermore, the percentage of MPA significantly
decreased (p < 0.05) at 3 h post-ingestion compared to baseline following ingestion of HI-NI beetroot
juice (Figure 4C).
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A time × trial interaction effect was evident for intermediate monocytes (p < 0.001), with an 
increase in the intermediate population at 6 h post-ingestion in the HI-NI, and a decrease in the 
LO-NI group (Table 4). A main effect of time was observed in classical monocytes. No other 
changes in monocyte subset populations across the assessed time-course were observed. 
Furthermore, there were no significant main effects, or interaction effects observed for P-selectin in 
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3.6. Whole Blood Coagulation 
There were no significant differences between trials at baseline for any of the ROTEM variables 
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with a significant decrease of 12.2 s in INTEM CT between baseline and 3 h post-ingestion in the 
Figure 4. Le flo cytometry analysis of: blood granulocytes (A,B); and monocytes (C,D).
Percent (%): CD16+CD14− granulocyte-platelet aggregates (GPA) (A); and CD14+ monocyte-platelet
aggregates (MPA) (C). Relative expression of Mac-1/αM integrin (CD11b+) on: granulocytes (B);
and monocytes (D), shown as median fluorescence intensity (MFI). Data expressed as mean± standard
deviation (SD), n = 12. Two-way ANOVA demonstrated a main effect of time and over the 0, 3 and
6 h time-course for MPA (p < 0.05) and granulocyte MFI (p < 0.01), with * significant (p < 0.05) and
** significant (p < 0.01) changes compared to pre-ingestion baseline (PRE) using Bonferroni’s post
hoc analysis.
3.4. Expression of CD11b in Granulocytes with HI-NO Beetroot Juice
The expression of CD11b (Mac-1/αM) on granulocytes (Figure 4B), but not monocytes (Figure 4D)
was decreased 3 h after ingestion of HI-NI beetroot juice (p < 0.01), as shown by post hoc analysis.
For granulocyte CD11b expressio , a time-dependent decrease (but no interaction effect) was observed
fol owing both the LO-NI and the HI-NO tr al (p < 0.05) (Figure 4B).
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3.5. Monocyte Subset Populations and Platelet P-Selectin Expression
A time × trial interaction effect was evident for intermediate monocytes (p < 0.001), with
an increase in the intermediate population at 6 h post-ingestion in the HI-NI, and a decrease in
the LO-NI group (Table 4). A main effect of time was observed in classical monocytes. No other
changes in monocyte subset populations across the assessed time-course were observed. Furthermore,
there were no significant main effects, or interaction effects observed for P-selectin in either group.
3.6. Whole Blood Coagulation
There were no significant differences between trials at baseline for any of the ROTEM variables
(Table 5). A significant effect of time was evident for INTEM CT (p < 0.05). Post hoc analysis showed
with a significant decrease of 12.2 s in INTEM CT between baseline and 3 h post-ingestion in the HI-NI
trial only (Table 5). There were no significant changes recorded in EXTEM CT, CFT, α angle or INTEM
CFT and α angle in either trial.
There were no effects for EXTEM or INTEM MCF. Analysis of the MCE revealed no significant
effects in either trial. A time × trial interaction effect was observed in APTEM CT (p < 0.05).
Furthermore, post hoc analysis showed a significant decrease in APTEM CT 6 h post-ingestion relative
to baseline for the HI-NI only (p < 0.05). No significant effects on LI30 were observed for EXTEM or
INTEM in either trial. No significant changes were observed for APTEM MCF.
3.7. Effects on Plasma Hemostasis Biomarkers
Clinical coagulation assays were performed on plasma to determine activity of the extrinsic
and intrinsic coagulation pathways. Baseline recordings of prothrombin time and activated partial
thromboplastin were not different between trials. All recorded prothrombin time and activated partial
thromboplastin time values were within reference ranges (Table 5). There was no significant interaction
effect, nor any main effects of trial or time for prothrombin time or activated partial thromboplastin
time assays (Table 5).
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Table 3. Total power spectral density measurements of systolic blood pressure and heart rate following nitrate-depleted (placebo) and nitrate-rich beetroot
juice ingestion.
Variable
LO-NI HI-NI 2-Way ANOVA
PRE 3 h POST 6 h POST PRE 3 h POST 6 h POST Time Treatment Time× Treatment
SBP variability, VLF, mmHg2 29.1 ± 4.7 26.6 ± 7.5 28.6 ± 8.1 29.9 ± 5.5 33.0 ± 10.5 27.6 ± 5.1 0.530 0.368 0.065
SBP variability, LF, mmHg2 24.7 ± 9.4 25.5 ± 7.1 26.7 ± 8.4 28.3 ± 9.9 31.5 ± 11.3 27.3 ± 8.1 0.578 0.258 0.389
SBP variability, HF, mmHg2 24.9 ± 9.2 24.6 ± 5.9 26.4 ± 9.2 26.2 ± 8.2 28.3 ± 11.7 24.5 ± 7.9 0.820 0.740 0.270
Heart rate, beats/min 68.9 ± 4.5 71.3 ± 8.4 69.8 ± 7.8 70.0 ± 6.8 73.7 ± 7.7 71.7 ± 7.4 0.059 0.499 0.857
Data indicated as mean values ± standard deviation (SD), n = 12. LO-NI, low-nitrate beetroot juice; HI-NI, high-nitrate beetroot juice; SBP, systolic blood pressure; VLF, very low frequency;
LF, low frequency; HF, high frequency; PRE, pre-ingestion (baseline); 3 h POST, 3 h post-ingestion; 6 h POST, 6 h post-ingestion.
Table 4. Flow cytometry analysis of monocyte subsets and P-selectin expression following nitrate-depleted (placebo) and nitrate-rich beetroot juice ingestion.
Variable
LO-NI HI-NI 2-Way ANOVA
PRE 3 h POST 6 h POST PRE 3 h POST 6 h POST Time Treatment Time× Treatment
Classical CD14++ CD16− monocytes 90.0 ± 4.1 91.6 ± 2.8 91.2 ± 3.7 91.1 ± 3.6 92.1 ± 3.2 89.7 ± 2.2 0.047 0.991 0.112
Intermediate CD14++ CD16+ monocytes 4.3 ± 1.5 3.9 ± 1.5 3.3 ± 1.6 * 4.0 ± 1.5 3.5 ± 1.3 4.9 ± 1.0 * 0.183 0.532 0.001
Non-classical CD14+ CD16++ monocytes 5.4 ± 2.7 4.4 ± 1.4 5.0 ± 2.4 4.2 ± 2.0 4.4 ± 2.1 5.4 ± 1.8 0.235 0.722 0.239
P-selectin (CD42a) 3083 ± 1657 3731 ± 1682 3104 ± 1202 3908 ± 1404 3810 ± 2073 3575 ± 1937 0.385 0.442 0.495
Data indicated as mean values ± standard deviation (SD), n = 12. * Significantly different from PRE values, p < 0.05; LO-NI, low-nitrate beetroot juice; HI-NI, high-nitrate beetroot juice;
PRE, pre-ingestion (baseline); 3 h POST, 3 h post-ingestion; 6 h POST, 6 h post-ingestion.
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Table 5. Measurement of hemostasis biomarkers following nitrate-depleted (placebo) and nitrate-rich beetroot juice ingestion.
Variable Reference Range
LO-NI HI-NI 2-Way ANOVA
PRE 3 h POST 6 h POST PRE 3 h POST 6 h POST Time Treatment Time× Treatment
Whole Blood Thromobelastometry
EXTEM CT, s 42–78 68.9 ± 4.4 71.5 ± 4.4 71.6 ± 5.0 70.3 ± 6.0 68.7 ± 4.7 68.3 ± 7.9 0.904 0.400 0.102
EXTEM CFT, s 53–144 91.8 ± 18.0 93.4 ± 17.2 91.8 ± 14.7 89.8 ± 16.5 94.3 ± 17.7 93.8 ± 21.3 0.271 0.969 0.533
EXTEM MCF, mm 48–70 65.8 ± 4.6 65.8 ± 4.1 66.2 ± 3.6 66.2 ± 3.5 65.3 ± 2.6 65.7 ± 3.7 0.429 0.867 0.495
EXTEM α angle, ◦ 63–83 72.6 ± 3.7 72.4 ± 3.3 72.8 ± 3.2 72.8 ± 3.0 72.1 ± 2.8 72.3 ± 4.0 0.389 0.781 0.304
EXTEM LI30, % 94–100 99.3 ± 0.9 98.8 ± 1.4 99.3 ± 0.8 98.8 ± 2.3 98.3 ± 2.1 99.1 ± 0.8 0.151 0.407 0.904
INTEM CT, s 134–218 208.0 ± 17.9 200.3 ± 15.0 199.0 ± 12.7 205.3 ± 18.5 193.1 ± 14.2 * 197.1 ± 20.8 0.010 0.490 0.698
INTEM CFT, s 52–116 72.6 ± 17.5 66.0 ± 13.5 67.7 ± 11.9 66.8 ± 14.7 66.8 ± 11.9 64.9 ± 12.3 0.180 0.614 0.279
INTEM MCF, mm 47–69 65.4 ± 4.6 65.7 ± 4.2 65.1 ± 3.7 66.3 ± 3.7 65.4 ± 3.3 66.3 ± 3.6 0.814 0.704 0.280
INTEM α angle, ◦ 70–83 75.3 ± 3.5 76.6 ± 2.7 76.1 ± 2.5 76.5 ± 2.8 76.5 ± 2.5 76.8 ± 2.5 0.247 0.562 0.287
INTEM LI30, % 94–100 99.7 ± 0.5 99.3 ± 1.2 99.3 ± 0.8 99.5 ± 0.7 98.4 ± 2.5 99.3 ± 0.8 0.066 0.367 0.378
APTEM CT, s 42–78 66.1 ± 5.4 67.6 ± 4.7 67.7 ± 3.6 68.8 ± 6.9 68.6 ± 5.2 64.8 ± 5.4 * 0.254 0.879 0.043
APTEM MCF, mm 48–70 66.3 ± 4.1 65.9 ± 4.2 65.8 ± 3.3 66.3 ± 4.3 65.3 ± 2.5 66.8 ± 3.7 0.234 0.954 0.232
FIBTEM MCF, mm 7–21 14.9 ± 4.3 14.8 ± 4.6 14.4 ± 4.0 14.5 ± 3.8 14.8 ± 3.8 14.9 ± 3.8 0.943 0.973 0.405
MCE 180.0 ± 37.5 178.7 ± 35.2 178.2 ± 25.8 181.6 ± 28.9 171.8 ± 21.2 176.7 ± 28.7 0.432 0.842 0.614
Plasma Hemostasis Analysis
Prothrombin time, s 11–15 11.9 ± 0.2 11.8 ± 0.2 11.8 ± 0.2 11.9 ± 0.2 12.0 ± 0.2 12.0 ± 0.2 0.851 0.605 0.508
Activated partial thromboplastin time, s 26–37 33.0 ± 1.0 32.5 ± 1.0 32.5 ± 1.0 32.8 ± 1.2 32.5 ± 1.2 32.5 ± 1.1 0.297 0.956 0.912
Data indicated as mean values ± standard deviation (SD), n = 12. * Significantly different from PRE values, p < 0.05. LO-NI, low-nitrate beetroot juice; HI-NI, high-nitrate beetroot juice;
PRE, pre-ingestion (baseline); 3 h POST, 3 h post-ingestion; 6 h POST, 6 h post-ingestion; EXTEM, extrinsically-activated test using tissue factor; assesses the extrinsic coagulation pathway;
INTEM, intrinsically-activated test using ellagic acid, assesses the intrinsic coagulation pathway; APTEM, extrinsically-activated test using the fibrinolysis inhibitor aprotinin, assesses
hyperfibrinolysis; FIBTEM, extrinsically-activated test using tissue factor and the platelet inhibitor cytochalasin D, assesses fibrin contribution to clot strength; CT, clotting time; CFT, clot
formation time; MCF. Maximum clot firmness; LI30, lysis index at 30 min; MCE, maximum clot elasticity.
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4. Discussion
This is the first study to investigate the acute effects of inorganic nitrate-rich versus
nitrate-depleted beetroot juice on the functional and phenotypic status of circulating leukocytes
and leukocyte-platelet aggregation in older adults. The most important findings were that, 3 h
following the consumption of beetroot juice naturally rich in inorganic nitrate, granulocyte and platelet
activation were decreased, and blood pressure was also decreased. A small increase was observed in
intermediate monocytes 6 h after nitrate-rich beetroot juice ingestion, but it is currently unclear whether
this represents an immune activation or pro-inflammatory response. From a practical perspective,
these findings are important for the application of beetroot juice (and possibly other nitrate-rich
foods) as a nutritional intervention to preserve cardiovascular health with aging. The observed
acute anti-thrombotic, anti-adhesive and blood pressure-lowering responses to beetroot juice may
accumulate over time, thereby reducing the long-term risk of developing vascular inflammation
and hypertension.
4.1. Effects of Nitrate-Rich Beetroot Juice on Plasma Nitrate and Nitrite
Following the ingestion of nitrate-rich beetroot juice, but not the placebo, plasma nitrate
concentration increased 3 h post-ingestion, and was still elevated 6 post-ingestion. This indicates
that the nitrate in the beetroot juice was absorbed in the gastro-intestinal tract and entered the
circulation, resulting in plasma nitrate levels of ≈400 µM 3 h post-ingestion. Comparable plasma
nitrate concentrations have been reported in healthy young men after administration of beetroot juice
containing 8.4 mmol (plasma nitrate ≈300 µM at 1 and 2 h post-ingestion), and 16.8 mmol nitrate
(≈600 µM at 2 h post-ingestion) [24]. Furthermore, we observed an increase in plasma nitrite to
≈300 nM 3 h and 6 h following the ingestion of the nitrate-rich beetroot juice only. This suggests that
the circulating nitrate originating from the beetroot juice was taken up by the salivary glands and
reduced to nitrite by oral commensal bacteria, and that nitrite in swallowed saliva reached the systemic
circulation [5–7]. In healthy young men, plasma nitrite concentrations increased to ≈400 nM 2 h after
ingestion of 6.8 mmol nitrate, and to ≈650 nM 4 h post-ingestion of 16.8 mmol nitrate [24]. Increases
in plasma nitrite have also been reported within three hours after a nitrate-rich meal (≈600 nM) [25]
and after short-term beetroot juice supplementation (≈1000 nM) [13] in older individuals. Potential
explanations for the differences in the plasma nitrite responses between our study and previous studies
in young [24] and older adults [13,25], include a longer supplementation period (2.5 days) [13] versus
single intake, inter-individual differences, and effects of aging. Smaller effects of dietary nitrate on
plasma nitrite concentrations might be expected in the older population due to age-related changes in
oral microbiota and an attenuated enterosalivary circuit [13,25].
4.2. Effects of Nitrate-Rich Beetroot Juice on Blood Pressure and Frequency Components of Blood
Pressure Variability
High blood pressure is a major risk factor for CVD [8,26]. The beneficial effects of the Dietary
Approaches to Stop Hypertension (DASH) on blood pressure have partly been attributed to the
high inorganic nitrate content of plant foods such as green leafy and root vegetables [5,8]. Although
a number of studies have shown blood pressure-lowering effects of dietary nitrate in young to
middle-aged individuals [8], our study is among a very few investigations that have involved healthy
older adults [9,10,13,14]. Our data showed decreases in mean arterial pressure, systolic and diastolic
blood pressure 3 h following the ingestion of nitrate-rich beetroot juice only. A recent study showed
decreases in blood pressure in tentatively healthy older individuals following 2.5 day-beetroot juice
supplementation [13]. Furthermore, three-week supplementation with beetroot juice reduced daily
systolic blood pressure, but not resting clinical blood pressure or 24-h ambulatory blood pressure in
older overweight individuals [9]. In contrast, Gilchrist et al. [14] reported no effects of 14 day-beetroot
juice supplementation on 24-h ambulatory blood pressure in older individuals with type 2 diabetes
mellitus. These variable effects of beetroot juice are potentially due to differences in the participants’
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health status. A diminished vascular reactivity and an impaired responsiveness to NO might have
attenuated or prevented any effects of beetroot juice on blood pressure in the individuals with type
2 diabetes [14]. Our data support the notion that dietary nitrate is a key component of a fruit and
vegetable-rich diet that can potentially help to reduce the risk of developing hypertension with
advancing age. Additional research is needed to substantiate these findings and to examine whether
these beneficial effects are sustained with long-term dietary nitrate intake.
By measuring beat-to-beat blood pressure in combination with power spectral analysis (PSD)
(Table 3), we aimed to identify individual blood pressure control mechanisms [17]. Blood pressure
control involves multiple mechanisms including pressure-volume regulation, the sympathetic nervous
system, hormonal regulation such as through the renin-angiotensin-aldosterone-system, and local
mechanisms such as the myogenic vascular response and NO [17,26]. The hypotensive effects of dietary
nitrate have mainly been attributed to peripheral vasodilation mediated by NO [11]. However, a recent
study by Notay et al. [27] showed that high-nitrate beetroot juice intake decreased muscle sympathetic
nerve activity at rest and during handgrip exercise in young healthy individuals. This suggests that the
mechanisms of action of dietary nitrate involve a neural contribution [27]. Contrary to these results [27],
our data suggest no sympathetic modulation of vascular tone by dietary nitrate, as assessed by PSD
analysis in the LF range. We also did not observe changes in the respiration-linked HF range. Factors
that could have contributed to these differences in the sympathetic nerve responses in the study
of Notay et al. [27] and ours include age and different measurement time-points (165–180 min in
the study by Notay et al. [27]). We observed a trend towards a difference between the responses to
nitrate-rich and nitrate-depleted beetroot juice in the VLF range, with an increase in the VLF range
3 h post-ingestion in the high nitrate trial only. The VLF domain has been linked to the myogenic
response of the vasculature [17]. Previous animal data have suggested that NO mediated smooth
muscle contraction through Ca2+ oscillation [28], whereas a more recent human study showed that
dietary nitrate increased skeletal muscle force without changing calcium handling [29]. Whether
our data are reflective of an increased myogenic vascular responsiveness needs to be addressed in
future studies.
4.3. Effects of Beetroot Juice on Markers of Vascular Inflammation and Platelet Activation
Accumulating data have shown that impaired immune function and low-grade inflammation
contribute to the development of major age-related diseases [15,30], particularly including CVD [1].
There is emerging evidence that suggests that dietary nitrate elicits anti-inflammatory and
anti-adhesive effects [6]. Previous research in rodents showed that dietary nitrate attenuated the
recruitment of leukocytes during acute vascular inflammation [31]. Another study demonstrated
inorganic nitrate-induced improvements in the inflammatory status of genetically modified,
atherosclerosis-prone mice, including a reduced neutrophil CD11b expression [32]. Thus far, however,
only few data are available on the influence of dietary nitrate on the inflammatory and thrombotic
profile in humans. Webb et al. reported an inhibitory effect on ex vivo platelet aggregation in plasma
that was collected 3 h after beetroot juice ingestion in healthy volunteers [11]. Velmurugan et al.
showed that six-week supplementation with nitrate-rich beetroot juice resulted in a reduction in
platelet-monocyte aggregates in patients with hypercholesterolemia [12]. In agreement with these
available human data, another key finding of this investigation was that nitrate-rich beetroot juice
reduced blood granulocytes expressing CD11b at 3 h post-ingestion relative to baseline. CD11b
(also known as Mac-1/αM) is a molecule involved in the recruitment of leukocytes to the endothelium.
Moreover, we observed a decrease in monocyte-platelet aggregation following nitrate-rich beetroot
juice intake only. Monocyte-platelet aggregation plays an important role in the development of
inflammation in vascular diseases [33], especially with aging [3], and is considered a reliable biomarker
for platelet activation. Notably, significant effects of time were observed in both groups in granulocyte
CD11b expression and monocyte-platelet aggregation. This possibly suggests additional effects
of bioactive ingredients other than nitrate contained in the beetroot juice and the apple that was
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part of the standardized breakfast [34]. Beetroot juice in particular contains a variety of potentially
bioactive phytochemicals, including betalains and flavonoids, some of which may particularly elicit
anti-thrombotic and anti-inflammatory effects [2,35].
When further characterizing monocyte population subsets, we observed an increase in circulating
intermediate CD14++CD16+ monocytes 6 h after nitrate-rich beetroot juice ingestion, and a decrease in
the placebo trial at the same time-point (Table 4). Intermediate monocytes have previously been related
to cardiovascular events in a patient population [36]. However, unlike the healthy participants of our
investigation, the patients of this previous study had a high burden of risk factors and cardiovascular
disease [36]. The clinical implications of the increase in intermediate monocytes after dietary nitrate
intake in healthy individuals are unclear. Additional research is also required to examine whether
these changes represents a transient phenotypic shift from classical CD14++CD16− to non-classical
CD14+CD16++ monocytes [22]. Together, most of the changes in thrombo-inflammatory markers
observed in our study suggest beneficial effects especially of nitrate, but possibly also other bioactive
compounds in beetroot juice.
4.4. Effects of Nitrate-Rich Beetroot Juice on Hemostasis
In addition to impaired immune function [15], alterations in hemostasis play a critical role in the
development of endothelial dysfunction and CVD with aging [3]. Dietary nitrate has been shown to
inhibit platelet aggregation in a number of studies in younger individuals [11,12,37]. A recent ex vivo
experiment demonstrated inhibitory effects of a NO donor on various blood coagulation processes
as measured by increased reaction time of fibrin formation, decreased rate of clot formation and
reduced clot strength [38]. Extending upon these studies that focused mainly on the effect of dietary
nitrate on platelet activation in younger adults, we investigated various components of coagulation in
a population of older adults. Applying thrombelastometry enabled us to comprehensively assess whole
blood coagulation [20] (Table 5). Our data showed subtle time-dependent changes in the clotting time
via the intrinsic coagulation pathway, as measured by the INTEM test, with a moderate, but significant
decrease in INTEM clotting time 3 h after nitrate-rich beetroot ingestion. Furthermore, there was
a small decrease in the APTEM clotting time (involving the extrinsic pathway) 6 h after nitrate-rich (but
not nitrate-depleted) beetroot juice intake. Notably, the observed changes in clotting times were within
clinical reference values. The plasma-based prothrombin time and activated partial thromboplastin
time have remained unchanged. It therefore appears unlikely that the observed minor changes
in secondary hemostasis are clinically relevant. Together with our findings on platelet-leukocyte
interaction, these data suggest that beetroot juice ingestion rather affects the primary hemostasis
pathway involving platelet activation and aggregation.
4.5. Theoretical and Practical Implications
We aimed to examine the effects of dietary nitrate in the form of concentrated beetroot juice as
a natural foodstuff rather than supplementing nitrate or nitrite salts. It is thought that the consumption
of a multitude of phytochemicals as part of a whole foods elicits additive and synergistic effects [2].
The observed significant decreases in granulocyte activation and monocyte-platelet aggregation
following both nitrate-rich and nitrite-depleted beetroot juice ingestion may support this concept.
Future research may use extracts containing candidate phytochemicals such as specific flavonoids to
identify the key bioactive compounds that appear to have contributed to the responses to beetroot
juice consumption. Furthermore, as part of a well-controlled study, we collected blood and monitored
blood pressure at the same time of the day to avoid circadian effects between the two trials. We cannot
exclude the possibility of circadian influences on blood pressure or immunological measurements
over the assessed time-period (i.e., from pre- to 6 h post-ingestion). Nor can we completely exclude
a possible interference of the medications (other than specified as exclusion criteria), used by some of
the participants. Notably though, we observed similar effects of nitrate-rich beetroot juice (such as
increases in plasma nitrate and nitrite, and decreases in blood pressure) in the individuals who used
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medications, as compared with the other participants. We also believe that our study population is
representative of what can be considered as clinically healthy older adults.
5. Conclusions
These data provide new insights into the acute effects of inorganic nitrate-rich as compared with
nitrate-depleted beetroot juice on blood pressure, circulating leukocyte phenotypes, platelet reactivity
and whole blood coagulation in a population of older adults. Our data confirm anti-thrombotic and
anti-adhesive properties of dietary nitrate that have previously been observed in studies in animals
and predominately young humans. Furthermore, our findings support the very few data available on
blood pressure-lowering effects of dietary nitrate in healthy older adults. Considering the evidence
suggesting anti-inflammatory effects of bioactive plant compounds in the long-term [2,30], it seems
very unlikely that the observed increase in intermediate monocytes reflects a shift toward chronic
low-grade inflammation. Most of the observed effects can be considered as beneficial for vascular
function. Together, our findings provide tentative support of the notion that the regular consumption
of beetroot juice could be a key component of lifestyle interventions to preserve cardiovascular health
with advancing age. However, long-term studies are warranted to test the benefits of natural beetroot
juice and potentially other inorganic nitrate-rich plant foods in this context.
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